Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review - Summary - MDSpire

Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review

  • By

  • Bassam Muthanna

  • Aadhila Abbas Manthiri

  • Leen Haj Saleh

  • Abdulrahman F. Al-Mashdali

  • Shehab F. Mohamed

  • June 8, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of tagraxofusp in adults with BPDCN and contextualize outcomes based on transplant eligibility.

Key Findings:
  • Twenty-seven studies included, representing 343 unique adult patients treated with tagraxofusp.
  • Frontline trials reported overall response rates (ORR) of 71%-90% and complete response rates (CR/CRc) of 56%-72%.
  • Real-world cohorts showed ORR of 65%-90%.
Interpretation:

Limitations:
  • Evidence is predominantly non-randomized.
  • Outcomes influenced by patient eligibility for HSCT.
  • Fragmented data across heterogeneous study designs.
Conclusion:

Original Source(s)

Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review

  • by Bassam Muthanna, Aadhila Abbas Manthiri, Leen Haj Saleh, Abdulrahman F. Al-Mashdali, Shehab F. Mohamed

  • June 8, 2026

Related Content

Digital Twins as catalysts for Whole Person Health Mind Body Medicine in Integrative Oncology

Mesonephric-like adenocarcinoma of the uterine corpus: a case report

Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression